Fürstenau, Moritz
Hopfinger, Georg
Robrecht, Sandra
Fink, Anna-Maria
Al-Sawaf, Othman http://orcid.org/0000-0001-9895-0570
Langerbeins, Petra
Cramer, Paula
Tresckow, Julia Von
Maurer, Christian
Kutsch, Nadine
Hoechstetter, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Döhner, Hartmut
Hensel, Manfred
Kiehl, Michael G.
Jaeger, Ulrich
Wendtner, Clemens-Martin
Goede, Valentin
Fischer, Kirsten
von Bergwelt-Baildon, Michael
Eichhorst, Barbara
Hallek, Michael
Theurich, Sebastian
Article History
Received: 17 June 2019
Revised: 14 October 2019
Accepted: 3 November 2019
First Online: 14 November 2019
Compliance with ethical standards
:
: GH reports personal fees from Novartis, personal fees from Celgene, and personal fees from Gildead outside the submitted work. A-MF reports personal fees (advisory board) from Janssen Pharmaceutical during the conduct of the study. OA-S reports Honoraria from Roche, Gilead, AbbVie, and Janssen. PL reports consultancy for Janssen, Sunesis, Mundipharma, and Roche, travel grants from Janssen, Mundipharma, and Roche, and research funding from Janssen, AbbVie, and Roche. PC reports consultancy for AbbVie, Acerta, Janssen, Novartis, and AstraZeneca, honoraria from AbbVie, Roche, and Janssen, research funding from AbbVie, Acerta, Roche, Gilead, GlaxoSmithKline, Janssen, and Novartis, and travel grants from AbbVie, Roche, Gilead, Janssen, and Mundipharma. JvT reports consultancy for Roche, Janssen, AbbVie, and Celgene, honoraria from AbbVie, Roche, and Janssen, travel grants from Roche, Janssen, and Celgene, and research funding from Roche and Janssen. NK reports research funding from Gilead and travel grants from Mundipharma, AbbVie, and Janssen. MH reports consultancy for Gilead and travel grants from Gilead, AbbVie, and Hexal. MD reports personal fees from Acerta, Bayer, Gilead, Novartis, and Sandoz, grants and personal fees from Celgene, Janssen, and Roche, and grants from Mundipharma outside the submitted work. MK reports personal fees from Roche and AbbVie. SS reports grants, personal fees, and nonfinancial support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics, and Sunesis outside the submitted work. HD reports personal fees from Agios, AbbVie, Amgen, Astellas, Astex, Celator, Celgene, Janssen, Jazz, Novartis, Seattle Genetics, and Sunesis and research funding from AROG, Bristol Myers Squibb, Celgene, Novartis, Pfizer, and Sunesis. C-MW reports grants and personal fees from Hoffmann-La Roche, and grants and personal fees from Mundipharma during the conduct of the study, grants and personal fees from Hoffmann-La Roche, Mundipharma, Janssen-Cilag, AbbVie, Gilead, Novartis, Celgene, and MorphoSys outside the submitted work. VG reports personal fees from Roche, Janssen, Gilead, and AbbVie outside the submitted work. KF reports personal fees (travel support) from Roche. MH reports research grants from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and AbbVie, and speakers bureau and advisory board for Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and Boehringer. BE reports research grants from AbbVie, Gilead, Janssen, Roche, and Beigene and personal fees and advisory boards from the same companies and Celgene and Novartis in addition. MF, SR, CM, EL, MH, MGK, MvB, and ST declare that they have no conflict of interest.